StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/309% below fair value
$8.04+0.07 (+0.88%)

Close on Nov 18, 2026Market cap $228.52MP/E –Yield –

Arcturus Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Arcturus Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$72.82M. For fiscal 2025 it was -$74.50M. The highest annual figure on record is $24.27M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$74.50M–
FY2024Dec 31, 2024-$60.40M–
FY2023Dec 31, 2023-$21.00M-186.5%
FY2022Dec 31, 2022$24.27M–
FY2021Dec 31, 2021-$138.45M–
FY2020Dec 31, 2020-$44.60M–
FY2019Dec 31, 2019-$7.26M–
FY2018Dec 31, 2018-$22.24M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.91M–
Q1 FY2026Mar 31, 2026-$19.44M–
Q4 FY2025Dec 31, 2025-$16.14M–
Q3 FY2025Sep 30, 2025-$17.33M–
Q2 FY2025Jun 30, 2025-$5.76M–
Q1 FY2025Mar 31, 2025-$35.28M–
Q4 FY2024Dec 31, 2024-$284.00K–
Q3 FY2024Sep 30, 2024-$23.84M–
Q2 FY2024Jun 30, 2024-$30.47M-160.4%
Q1 FY2024Mar 31, 2024-$5.80M–
Q4 FY2023Dec 31, 2023-$1.50M-101.0%
Q3 FY2023Sep 30, 2023-$33.39M–
Q2 FY2023Jun 30, 2023$50.45M–
Q1 FY2023Mar 31, 2023-$36.56M–
Q4 FY2022Dec 31, 2022$156.45M–
Q3 FY2022Sep 30, 2022-$44.59M–
Q2 FY2022Jun 30, 2022-$36.44M–
Q1 FY2022Mar 31, 2022-$51.15M–
Q4 FY2021Dec 31, 2021-$43.62M–
Q3 FY2021Sep 30, 2021-$18.42M–
Q2 FY2021Jun 30, 2021-$33.35M–
Q1 FY2021Mar 31, 2021-$43.07M–
Q4 FY2020Dec 31, 2020-$7.33M–
Q3 FY2020Sep 30, 2020-$16.31M–
Q2 FY2020Jun 30, 2020-$8.96M-198.8%
Q1 FY2020Mar 31, 2020-$12.00M–
Q4 FY2019Dec 31, 2019-$7.85M–
Q3 FY2019Sep 30, 2019-$3.00M–
Q2 FY2019Jun 30, 2019$9.07M–
Q1 FY2019Mar 31, 2019-$5.49M–
Q4 FY2018Dec 31, 2018-$5.99M–
Q3 FY2018Sep 30, 2018-$7.05M–

More Arcturus Therapeutics figures

See a number that looks wrong?